DUBLIN – Decision time is looming for Sterna Biologicals GmbH & Co. KG on the development trajectory of its first-in-class GATA-3 inhibition program, which has delivered promising, if preliminary, data in ulcerative colitis, asthma, atopic dermatitis, and chronic obstructive pulmonary disease.